PharmiWeb.com - Global Pharma News & Resources
07-Feb-2019

Global Testicular Cancer Drugs Market Outlook, 2019-2023 with Baxter, Bristol-Myers Squibb, Eli Lilly, Pfizer, and Teva Pharmaceutical Leading - ResearchAndMarkets.com

The "Global Testicular Cancer Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The testicular cancer drugs market will register a CAGR of over 4% by 2023.

The availability of combination therapies for the treatment of testicular cancer will drive market growth during the forecast period. Combined drug therapy is more effective compared with single-drug therapy. Researchers are focused on the development of new combination therapies because of their effectiveness in treating testicular cancer.

Increasing prevalence of testicular cancer

There has been an increase in the prevalence of testicular cancer globally. Estrogenic activity results in hormonal disruption and is responsible for the gradually increasing incidence of testicular cancer. In 2015, in the US, 17.52% of the total population of men were living with testicular cancer.

Alternative treatment options

The market has alternative treatment options for testicular cancer, including radiation therapy and surgery. Surgery is the first-line treatment in most cases and is generally curative. Radiation therapy is a method in which high-energy X-rays are used to destroy cancer cells. These alternative treatment methods may limit the consumption of drugs and pose a challenge to the market.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of few countries. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Comparison by type
  • Non-seminoma - Market size and forecast 2018-2023
  • Seminoma - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/266tmx/global_testicular?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005473/en/

Editor Details

Last Updated: 07-Feb-2019